Gerber Products Company logo, baby food and baby product brand, graphic element on white via Associated Press
Contamination concerns have forced Gerber to pull some of its baby formula from store shelves.
Gerber parent company Perrigo issued a voluntary recall of Gerber's Good Start SoothePro Infant Formula "out of an abundance of caution" regarding a link to possible Cronobacter sakazakii contamination.
The impacted products were manufactured in Eau Claire, Wisconsin between January 2 and January 18.
"Importantly, no distributed product has tested positive for the presence of this bacteria, no adverse events have been reported and no other products manufactured at this facility or any other of Perrigo's facilities are affected by this recall," the company said in a statement.
Cronobacter sakazakii is a bacteria that is relatively common and typically does not impact most people, but when newborns and infants with compromised immune systems are exposed, it can potentially cause sepsis and meningitis, according to the Centers for Disease Control and Prevention.
"Every batch of infant formula is tested to make certain it meets stringent nutritional, safety, quality and regulatory requirements," Perrigo Company stated.
The recall comes just a month after an Enfamil baby formula recall due to concerns over the same kind of contamination.
Seth Schachner, Managing Director at Strat Americas, breaks down Disney’s Q3 results: streaming profits, parks growth and ESPN rights deal with the NFL.
Kory Kantenga, Head of Economics Americas at LinkedIn, unpacks Friday’s jobs numbers, labor force trends, and signals of a potential economic deal with China.
Bret Kenwell, US Investment Analyst at eToro, joins us to break down tech earnings, what’s driving tech stock momentum, and what investors should watch next.
Citigroup’s Global Chief Economist, Nathan Sheets, breaks down the Fed’s decision to hold rates, Trump’s reaction, and the likelihood of a cut this fall.
Tony Edward discusses Ethereum’s rise, governance of corporate crypto treasuries, the newly signed GENIUS Act, and the pending CLARITY Market Structure Act.
